MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14796694.2026.2672129

Медицинская библиотека · Future oncology (London, England) · 2026

SOME: sintilimab plus chemotherapy followed by definitive local therapy for oligometastatic thoracic esophageal squamous cell carcinoma-a multicenter, prospective, open-label phase II trial.

Zhang Kanghua, Wang Chenchen, Mo Han, Zhao Jia, Li Xiangnan, Zhang Guoqing

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

First-line therapy for recurrent or metastatic esophageal squamous cell carcinoma (ESCC) currently consists of a programmed cell death protein 1 inhibitor plus platinum-based chemotherapy. Previous studies have indicated selected patients with synchronous oligometastatic ESCC may benefit from intensified curative-intent local therapy; however, prospective trials dedicated to treating patients with this specific disease are lacking. The SOME trial will prospectively explore whether patients with synchronous oligometastatic thoracic ESCC who undergo protocol-defined curative-intent local treatment after systemic therapy may have more favorable overall survival than patients with polymetastatic disease treated with systemic therapy alone. In this phase II trial, systemic anticancer therapy-naive thoracic ESCC patients will be enrolled and assigned by stage and metastatic burden to cohort A (locally advanced resectable), cohort B (synchronous oligometastatic ESCC), or cohort C (polymetastatic ESCC not meeting oligometastatic disease criteria). A total of 148 patients will be enrolled (37 in cohort A, 37 in cohort B, and 74 in cohort C). All patients will receive sintilimab plus platinum-based chemotherapy, and cohorts A and B will additionally receive curative-intent local therapy. The primary endpoint is overall survival. The secondary endpoints are progression-free survival and disease-free survival, among others.Clinical trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR2500108825.

Для цитирования: Zhang Kanghua, Wang Chenchen, Mo Han, Zhao Jia, Li Xiangnan, Zhang Guoqing. SOME: sintilimab plus chemotherapy followed by definitive local therapy for oligometastatic thoracic esophageal squamous cell carcinoma-a multicenter, prospective, open-label phase II trial.. Future oncology (London, England). 2026. DOI: 10.1080/14796694.2026.2672129.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.